Clinical Trials Logo

Filter by:
NCT ID: NCT06155565 Not yet recruiting - Anxiety Disorder Clinical Trials

Understanding Patient Engagement Trends in Anxiety Disorder Clinical Research

Start date: December 2024
Phase:
Study type: Observational

Clinical trials, specifically focused on anxiety disorder, are crucial in assessing the safety and efficacy of new treatments. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation. The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.

NCT ID: NCT06155552 Not yet recruiting - Weight Loss Clinical Trials

Evaluating the Occurrence of Participation Trends Among Weight Loss Clinical Trials Patients

Start date: December 2024
Phase:
Study type: Observational

Clinical studies, with a distinct focus on weight loss, play a crucial role in evaluating the safety and effectiveness of novel treatments. These trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption. The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this specific patient group.

NCT ID: NCT06155357 Not yet recruiting - Atrial Fibrillation Clinical Trials

A Study of a Lifestyle Program on Recurrent Atrial Fibrillation

Start date: September 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the impact of a comprehensive lifestyle intervention, including cardiac rehabilitation, prior to catheter ablation (a procedure to stop abnormal electrical signals in the heart), on Atrial Fibrillation (AF)-related symptoms.

NCT ID: NCT06154590 Not yet recruiting - Chronic Pain Clinical Trials

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor

NASBP-B-09
Start date: July 2024
Phase:
Study type: Observational [Patient Registry]

At a median follow-up of 33 months, the combination of anastrozole and NOLVADEX (tamoxifen citrate) did not demonstrate any efficacy benefit when compared to NOLVADEX (tamoxifen citrate) therapy given alone in all patients as well as in the hormone receptor positive subpopulation. This treatment arm was discontinued from the trial. This study is now a combination therapy whereas the median duration of adjuvant treatment for safety evaluation is 59.8 months and 59.6 months for patients receiving anastrozole 1 mg and NOLVADEX (tamoxifen citrate) 20 mg, respectively.

NCT ID: NCT06154304 Not yet recruiting - Bronchial Asthma Clinical Trials

BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma

Start date: December 11, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product, using bronchoprovocation (methacholine challenge testing) in adult patients with stable mild asthma.

NCT ID: NCT06152627 Not yet recruiting - Clinical trials for Muscle Tension Dysphonia

Voice Therapy Per the Rehabilitation Treatment Specification System

RTSS-Voice
Start date: September 1, 2024
Phase:
Study type: Observational

The goal of this study is to evaluate if using evidence-based, standard ingredient and target codes from the Rehabilitation Treatment Specification System - Voice Therapy (RTSS-Voice) in standard of care voice therapy documentation can improve outcomes for patients with muscle tension dysphonia (MTD). The main question it aims to answer is: Since the RTSS-Voice will help clinicians think about their treatment more specifically and in relation to nine evidence-based therapies, will its adoption be associated with improved outcomes? Clinicians across five voice centers will be asked to use the RTSS-Voice to document their voice therapy sessions for patients with MTD. Researchers will compare changes in outcomes between two groups of patients: those treated during the clinician's first year using the RTSS-Voice versus those treated during the clinician's second year using the RTSS-Voice.

NCT ID: NCT06150976 Not yet recruiting - Cancer Clinical Trials

MAAT For Young Adult Cancer Survivors

MAAT-YACCS
Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to pilot-test a modified version of telehealth-delivered Memory and Attention Adaption Training (MAAT) that is tailored to young adult childhood cancer survivors (ages 18-39; MAAT-YS) with cancer-related cognitive impairment (CRCI). MAAT-YS consists of 8 weekly visits (45-minutes in duration) and participants use a survivor workbook and complete homework between visits. Participants in this single-group pilot trial (N=9) will complete online self-report measures of cognitive symptoms, quality of life, treatment satisfaction and a brief online neuropsychological test battery at baseline and post-MAAT-YS timepoints.

NCT ID: NCT06150612 Not yet recruiting - Migraine Clinical Trials

Unwinding Anxiety for Migraine: Pilot

UAM
Start date: January 3, 2024
Phase: N/A
Study type: Interventional

This is a pilot study that aims to understand the feasibility and acceptability of a mobile health educational app plus group-based mindfulness therapy on anxiety and migraine-related disability among people with migraine.

NCT ID: NCT06150599 Not yet recruiting - Clinical trials for Chronic Pelvic Pain Syndrome

Sacral Neuromodulation for Chronic Pelvic Pain

SNM_CPP
Start date: July 2024
Phase: N/A
Study type: Interventional

Sacral neuromodulation (SNM) is a safe, effective, and minimally invasive FDA approved treatment for urinary and fecal incontinence, urinary frequency, urgency, and urinary retention. In this study we are assessing the effectiveness of sacral neuromodulation in women with suffering from chronic pelvic pain (CPP), through a single device implant procedure.

NCT ID: NCT06149455 Not yet recruiting - Nephrolithiasis Clinical Trials

Preoperative Prophylactic Antibiotic Duration in Moderate to High Risk Ureteroscopy

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The goal of this non-inferiority randomized controlled trial: is to test the hypothesis that the that there is no additional benefit from a longer course (7 days) versus a shorter course (2 days) of pre-operative antibiotics in patients with moderate to high risk of infection undergoing ureteroscopy. The main questions it aims to answer are: 1. Determine the safety and efficacy of a short course (2 days) as compared to a long course (7 days) 2. Identify secondary predictors of post-operative infectious complications